May. 5 at 8:32 PM
$SDGR
🚨🚨🚨🚨
Schrödinger, Inc. reported first quarter 2026 revenue of
$58.6 million, down 2% from a year earlier, as it advances a shift to hosted software.
Annual contract value (ACV) was
$28.4 million for the quarter and
$201 million on a trailing four-quarter basis, reflecting 12% growth.
Software revenue declined 21% to
$35.6 million, while drug discovery revenue more than doubled to
$22.9 million.
Net loss was
$60.0 million, or
$0.81 per share, and adjusted EBITDA was a loss of
$37.7 million.
The company ended the quarter with
$406 million in cash, cash equivalents, restricted cash and marketable securities and reaffirmed 2026 guidance, including ACV of
$218–
$228 million and drug discovery revenue of
$55–
$65 million.
Schrödinger also highlighted its upcoming agentic AI “co-scientist” Bunsen and the announced up to
$2.3 billion sale of co-founded Ajax Therapeutics, in which it held a 5.8% equity stake as of year-end 2025.
